Recently, the 2024 International Pharmaceutical Service Industry Innovation and Development Conference and the 9th China Pharmaceutical R&D Innovation Summit opened at the Xiong'an Convention and Exhibition Center. Among them, the highly anticipated 2024 China Traditional Chinese Medicine Research and Development Strength Ranking has been officially released. Jiangsu Kangyuan Pharmaceutical Co., Ltd. once again won the first place on the "Chinese Medicine List", indicating that Kangyuan Pharmaceutical's research and development strength and innovation level have been recognized by the expert committee and fully recognized by the industry. This summit focuses on the direction of "new drug research and clinical trials", inviting multiple academicians to attend and gathering hundreds of industry experts from politics, industry, medicine, academia, research, and capital. It is aimed at professionals in the pharmaceutical industry research and clinical research, jointly exploring the development trend of innovative drugs, innovation in the biopharmaceutical industry chain, cutting-edge technology, clinical trials, and exploring the core value of commercialization of innovative drug enterprises, effectively promoting the construction of the pharmaceutical innovation ecosystem and new quality productivity, and accelerating the high-quality development of China's innovative drug industry. The 2024 China Traditional Chinese Medicine R&D Strength Ranking and other rankings are calculated proportionally by Yaozhi.com, the Expert Committee of Drug R&D Strength Ranking, and the Organizing Committee of the 2024 China Pharmaceutical R&D Innovation Summit based on the scores of domestic drug acceptance and approval, R&D investment, clinical trial scores, foreign drug R&D status, patent scores, and historical drug R&D ranking scores (2023) of the enterprise in 2023. As a leading enterprise in traditional Chinese medicine research and development innovation, Kangyuan Pharmaceutical adheres to the innovative spirit of "Bosi Jingyi, Houpu Yuanzhi", has been immersed in traditional Chinese medicine technology innovation for 30 years, and is committed to the standardization, intelligence, and internationalization research of traditional Chinese medicine. Guided by traditional Chinese medicine theory, it focuses on the advantages of traditional Chinese medicine, applies cutting-edge modern drug research and development technology, develops innovative traditional Chinese medicine drugs with clearer material foundations, clearer mechanisms, more refined formulations, and more accurate indications, promotes industrial innovation through technological innovation, promotes high-quality development of the traditional Chinese medicine industry, and accelerates the formation of new productive forces in the traditional Chinese medicine industry. With the national key laboratory for process control and intelligent manufacturing technology of traditional Chinese medicine and the national and local joint engineering research center for intelligent manufacturing technology of traditional Chinese patent medicines and simple preparations as the core, Kangyuan Pharmaceutical integrates scientific research platforms at all levels, such as the national postdoctoral research workstation, as well as laboratories jointly built by schools and enterprises, forming a multi-level, three-dimensional comprehensive scientific and technological innovation carrier covering "innovative traditional Chinese medicine discovery - new drug research and development - intelligent manufacturing - post marketing re evaluation", has undertaken more than 40 national science and technology projects, such as the 973 Plan, the 863 Plan, and major new drug innovation, authorized more than 600 invention patents, and was selected into the first batch of "R&D institutions of enterprises with international influence (the first level)" cultivation bank in Jiangsu Province. The company first proposed the system decoding theory of traditional Chinese patent medicines and simple preparations with functional substances as the core, providing a theoretical basis for the "what to control" and "how to control" of the complex ingredient system in the process of traditional Chinese medicine manufacturing; Innovate the discovery technology of functional composition of traditional Chinese patent medicines and simple preparations, and develop the first innovative drug targeting PAF receptor for ischemic stroke functional composition combination; Pioneering a full process quality control system with functional ingredients as the core, achieving "dynamic overall quality control throughout the process" and significantly improving product uniformity; It pioneered the intelligent manufacturing technology of traditional Chinese patent medicines and simple preparations and broke through the bottleneck of big data collection, analysis and application in the pharmaceutical industry; The technological achievements have won one second prize of the National Technology Invention Award, three second prizes of the National Science and Technology Progress Award, and two Chinese Patent Gold Awards, continuously injecting technological momentum into the development of new productive forces in the traditional Chinese medicine industry. In the future, Kangyuan Pharmaceutical will continue to adhere to innovation driven development, continuously enhance independent innovation capabilities, continuously promote high-quality development of the enterprise, and develop innovative drugs with clinical advantages and characteristics; Adhere to an open mindset, continuously strengthen cooperation and communication with the industry, gather consensus, and better play a leading role in innovation in the traditional Chinese medicine industry. (Lai Xin She)